ATARA Biotherapeutics (ATRA) Granted FDA Clearance to Proceed with Enrollment at U.S. Sites for Ongoing Global Phase 1 Clinical Study to Evaluate ATA188
Go back to ATARA Biotherapeutics (ATRA) Granted FDA Clearance to Proceed with Enrollment at U.S. Sites for Ongoing Global Phase 1 Clinical Study to Evaluate ATA188| (NASDAQ: ATRA) | Delayed: 0.71 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.71 | 52 Week High | $40.80 | |||
| Open | $0.71 | 52 Week Low | $12.45 | |||
| Day High | $0.71 | P/E | N/A | |||
| Day Low | $0.71 | EPS | $0.00 | |||
| Volume | 20 | |||||
